Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial
Authors: Zamboni Paolo , Galeotti Roberto , Salvi Fabrizio , Giaquinta Alessia , Setacci Carlo , Alborino Salvatore , Guzzardi Giuseppe , Sclafani Salvatore J. , Maietti Elisa , Veroux Pierfrancesco ,   for the Brave Dreams Investigators, Barbarossa Elena , Bartolomei Ilaria , Ceruti Stefano , Conforti Paolo , Malagoni Anna Maria , Menegatti Erica , Tessari Mirko , Pellegrino Lisa , Pancaldi Francesca , Vanini Maria Elena , Piscaglia Maria Grazia , Cenni Patrizia , Rasi Fabrizio , Babini Mara , Drea Antonella , Guerrini Eugenia , Lotti Enrico Maria , Morelli Agnese , Peroni Milena , Zalambani Valentina , Zecchini Sauro , Chisari Clara , Chiaramonte Ignazio , Cimino Vincenzo , Di Pino Luigi , Failla Gianni , Cantello Roberto , Leone Maurizio , Coppo Lorenzo , Raymkulova Olga , Ruggerone Simona , Stecco Alessandro , Vecchio Domizia , Confalonieri Paolo Agostino , Ciceri Elisa , Danni Maura , Belleggia Carla , Luccioni Giuseppe , Oncini Luigi , Quatrini Cristina 
Published: November 2019

Purpose:

To evaluate if jugular vein flow restoration in various venographic defects indicative of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis (MS) patients can have positive effects on cerebral lesions identified using magnetic resonance imaging (MRI).

Materials and Methods:

The Brave Dreams trial ( ClinicalTrials.gov identifier NCT01371760) was a multicenter, randomized, parallel group, double-blind, sham-controlled trial to assess the efficacy of jugular venoplasty in MS patients with CCSVI. Between August 2012 and March 2016, 130 patients (mean age 39.9±10.6 years; 81 women) with relapsing/remitting (n=115) or secondary/progressive (n=15) MS were randomized 2:1 to venography plus angioplasty (n=86) or venography (sham; n=44). Patients and study personnel (except the interventionist) were masked to treatment assignment. MRI data acquired at 6 and 12 months after randomization were compared to the preoperative scan for new and/or >30% enlargement of T2 lesions plus new gadolinium enhancement of pre-existing lesions. The relative risks (RR) with 95% confidence interval (CI) were estimated and compared. In a post hoc assessment, venograms of patients who underwent venous angioplasty were graded as “favorable” (n=38) or “unfavorable” (n=30) for dilation according to the Giaquinta grading system by 4 investigators blinded to outcomes. These subgroups were also compared.

Results:

Of the 130 patients enrolled, 125 (96%) completed the 12-month MRI follow-up. Analysis showed that the likelihood of being free of new cerebral lesions at 1 year was significantly higher after venoplasty compared to the sham group (RR 1.42, 95% CI 1.00 to 2.01, p=0.032). Patients with favorable venograms had a significantly higher probability of being free of new cerebral lesions than patients with unfavorable venograms (RR 1.82, 95% CI 1.17 to 2.83, p=0.005) or patients in the sham arm (RR 1.66, 95% CI 1.16 to 2.37, p=0.005).

Conclusion:

Expanded analysis of the Brave Dreams data that included secondary/progressive MS patients in addition to the relapsing/remitting patients analyzed previously showed that venoplasty decreases new cerebral lesions at 1 year. Post hoc analysis confirmed the efficacy of the Giaquinta grading system in selecting patients appropriate for venoplasty who were more likely to be free from accumulation of new cerebral lesions at MRI.